• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Vera Therapeutics Inc.

    11/4/24 7:49:25 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    SC 13D/A 1 d811011dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    VERA THERAPEUTICS, INC.

    (Name of Issuer)

    Class A Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    92337R101

    (CUSIP Number)

    Patrick G. Enright

    Managing Member

    Longitude Capital Partners IV, LLC

    2740 Sand Hill Road, 2nd Floor

    Menlo Park, CA 94025

    (650) 854-5700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Longitude Capital Partners IV, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    AF

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    0

       8   

    SHARED VOTING POWER

     

    3,429,927 (1)

       9   

    SOLE DISPOSITIVE POWER

     

    0

        10   

    SHARED DISPOSITIVE POWER

     

    3,429,927 (1)

     11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,429,927 (1)

     12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

     13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    5.5% (2)

     14   

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1)

    All shares are held of record by LVPIV (as defined in Item 2(a) below). LCPIV (as defined in Item 2(a) below) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its prospectus supplement dated October 30, 2024 and filed with the Securities and Exchange Commission (the “Commission”) on October 30, 2024 (the “Prospectus Supplement”).


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Longitude Venture Partners IV, L.P.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    WC

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    0

       8   

    SHARED VOTING POWER

     

    3,429,927 (1)

       9   

    SOLE DISPOSITIVE POWER

     

    0

        10   

    SHARED DISPOSITIVE POWER

     

    3,429,927 (1)

     11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,429,927 (1)

     12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

     13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    5.5% (2)

     14   

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    All shares are held of record by LVPIV. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Longitude Prime Partners, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    AF

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    0

       8   

    SHARED VOTING POWER

     

    1,714,285 (1)

       9   

    SOLE DISPOSITIVE POWER

     

    0

        10   

    SHARED DISPOSITIVE POWER

     

    1,714,285 (1)

     11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,714,285 (1)

     12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

     13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    2.8% (2)

     14   

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1)

    All such shares are held of record by LPF (as defined in Item 2(a) below). LPP (as defined in Item 2(a) below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Longitude Prime Fund, L.P.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    WC

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    0

       8   

    SHARED VOTING POWER

     

    1,714,285 (1)

       9   

    SOLE DISPOSITIVE POWER

     

    0

        10   

    SHARED DISPOSITIVE POWER

     

    1,714,285 (1)

     11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,714,285 (1)

     12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

     13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    2.8% (2)

     14   

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    All such shares are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Patrick G. Enright

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    AF

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    39,850 (1)

       8   

    SHARED VOTING POWER

     

    5,144,212 (2)(3)

       9   

    SOLE DISPOSITIVE POWER

     

    39,850 (1)

        10   

    SHARED DISPOSITIVE POWER

     

    5,144,212 (2)(3)

     11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,184,062 (1)(2)(3)

     12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

     13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    8.4% (4)

     14   

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1)

    Consists of shares of Class A Common Stock underlying stock options granted to Patrick Enright, in his capacity as a member of the Issuer’s board of directors, which are exercisable within 60 days of the date hereof.

    (2)

    All shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Consists of (i) 3,429,927 outstanding shares of Class A Common Stock held of record by LVPIV and (ii) 1,714,285 outstanding shares of Class A Common Stock held of record by LPF.

    (4)

    Based on 61,999,281 shares, which is the sum of (i) 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement plus (ii) 39,850 shares of Class A Common Stock underlying stock options granted to Patrick Enright, in his capacity as a member of the Issuer’s board of directors, which are exercisable within 60 days of the date hereof.


    CUSIP No. 92337R101    13D

     

    1   

    NAMES OF REPORTING PERSONS

     

    Juliet Tammenoms Bakker

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3   

    SEC USE ONLY

     

    4   

    SOURCE OF FUNDS (see instructions)

     

    AF

    5   

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ☐

    6   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       7   

    SOLE VOTING POWER

     

    0

       8   

    SHARED VOTING POWER

     

    5,144,212 (1)(2)

       9   

    SOLE DISPOSITIVE POWER

     

    0

       10   

    SHARED DISPOSITIVE POWER

     

    5,144,212 (1)(2)

    11   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,144,212 (1)(2)

    12   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    13   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    8.3% (3)

    14   

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1)

    All shares are held of record by LVPIV and LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the Issuer’s board of directors, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 3,429,927 outstanding shares of Class A Common Stock held of record by LVPIV and (ii) 1,714,285 outstanding shares of Class A Common Stock held of record by LPF.

    (3)

    Based on 61,959,431 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.


    CUSIP No. 92337R101    13D

     

    Item 1. Security and Issuer.

    This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Class A Common Stock, par value $0.001 per share (“Common Stock”), of Vera Therapeutics, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 8000 Marina Boulevard, Suite 120, Brisbane, California 94005.

    Item 2. Identity and Background.

    (a) This Amendment No. 4 (“Amendment No. 4”) amends and supplements the Schedule 13D originally filed with the Commission on May 27, 2021 as amended by Amendment No. 1 filed with the Commission on April 5, 2022, Amendment No. 2 filed with the Commission on February 16, 2023 and Amendment No. 3 filed with the Commission on February 5, 2024 (the “Original Schedule 13D”). This Statement is being filed by Longitude Venture Partners IV, L.P. (“LVPIV”), Longitude Capital Partners IV, LLC (“LCPIV”), Longitude Prime Partners, LLC (“LPP”) and Longitude Prime Fund, L.P. (“LPF”, and together with LVPIV, LCPIV and LPP, the “Reporting Entities”) and Juliet Tammenoms Bakker (“Tammenoms Bakker”) and Patrick G. Enright (“Enright” and together with Tammenoms Bakker, the “Reporting Individuals”), a member of the Issuer’s board of directors (the “Board”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to Amendment No. 2 as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person. This Amendment No. 4 is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with a disposition of any shares by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Statement have the meanings ascribed to them in the Original Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    (a) and (b) See Items 7-11 of the cover pages of this Statement and Item 2 above.

    (c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

    (d) Under certain circumstances set forth in the limited partnership agreements of LVPIV and LPF, the general and limited partners may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Original Schedule 13D is hereby amended to add the following language:

    On October 31, 2024, the Issuer completed a public offering pursuant to which the Issuer issued and sold 7,142,858 shares of Class A Common Stock at a price to the public of $42.00 per share (the “October 2024 Follow-on Offering”). In connection with the October 2024 Follow-on Offering, LVPIV has entered into a lock-up agreement, pursuant to which LVPIV agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer’s securities held by LVPIV for 45 days following the date of the final prospectus for the October 2024 Follow-on Offering. The terms and provisions of such lock-up agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 9 to this Statement and is incorporated herein by reference.


    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 9:
       Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (included as Exhibit A to the form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s Current Report on Form 8-K as filed with the Commission on October 31, 2024).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 4, 2024

     

    LONGITUDE VENTURE PARTNERS IV, L.P.
    By:   LONGITUDE CAPITAL PARTNERS IV, LLC
    Its:   General Partner
    By:   /s/ Cristiana Blauth Oliveira
      Cristiana Blauth Oliveira, Authorized Signatory
    LONGITUDE CAPITAL PARTNERS IV, LLC
    By:   /s/ Cristiana Blauth Oliveira
      Cristiana Blauth Oliveira, Authorized Signatory
    LONGITUDE PRIME FUND, L.P.
    By:   LONGITUDE PRIME PARTNERS, LLC
    Its:   General Partner
    By:   /s/ Cristiana Blauth Oliveira
      Cristiana Blauth Oliveira, Authorized Signatory
    LONGITUDE PRIME PARTNERS, LLC
    By:   /s/ Cristiana Blauth Oliveira
      Cristiana Blauth Oliveira, Authorized Signatory

     

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright

    Patrick G. Enright

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker

    Get the next $VERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    1/8/2024Overweight
    Cantor Fitzgerald
    12/18/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/1/24 5:58:54 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:10:28 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:05:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 1:22:39 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

      BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

      11/18/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

      BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

      7/1/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

      BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

      6/11/24 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Fordyce Marshall sold $546,914 worth of shares (19,688 units at $27.78), decreasing direct ownership by 9% to 204,665 units (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/27/25 4:05:29 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R was granted 10,740 shares, increasing direct ownership by 21% to 61,946 units (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/20/25 4:13:15 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Turner William D. was granted 22,500 shares (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/20/25 4:11:50 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Financials

    Live finance-specific insights

    See more
    • Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

      BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

      1/13/25 7:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

      New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

      6/17/23 10:10:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

      Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)

      1/30/23 6:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $VERA
    SEC Filings

    See more
    • Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March

      5/6/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on April 3, 2025 has an exercise price per share equal to $22.74, Vera's closing trading price on April

      4/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

      On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). "We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing

      4/3/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

      5/5/25 9:37:24 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Vera Therapeutics with a new price target

      Wolfe Research initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $49.00

      2/4/25 7:12:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vera Therapeutics with a new price target

      Goldman initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $58.00

      1/28/25 8:54:12 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      5/6/25 8:00:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vera Therapeutics Inc.

      DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:08:41 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Vera Therapeutics Inc.

      DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:06:57 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care